Immunovant Inc Fireside Chat Hosted by LifeSci Capital Transcript
We're joined today by Dr. Peter Salzmann, the company's CEO. And in terms of format, there will be a presentation on the background and positioning of Immunovant FcRn inhibitors and then this will be followed up for some Q&A. And with that, over to you, Pete. Thanks, Sam.
And I appreciate the invitation to be a good amount of material. So I'm going to, as you mentioned, go through that material, then we'll have plenty of time for Q&A. We'll be making some forward-looking statements today, and I direct investors to carefully read this statement, which is part of the 8-K where we released this slide deck this morning. Just for a quick orientation. These are the programs that we have in development across our 2 assets, pitolimab and 1402 today, post education on a lot of preclinical biology related to 1402. And then also, you talk about chronic inflammatory demyelinating polyneuropathy or CIDP in our program there.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
